Galderma planning Phase III program for atopic dermatitis therapy

Galderma said nemolizumab met the primary endpoint in a Phase IIb trial to treat adults with moderate-to-severe atopic dermatitis not adequately controlled by topical corticosteroids. The company plans to start a Phase III program of the humanized mAb against IL-31 receptor α by mid-year.

Galderma is the medical solutions business of the Nestlé Skin Health unit of Nestle S.A. (SIX:NESN)...